Source: https://www.law.cornell.edu/uscode/text/21/379d-4?qt-us_code_tabs=1
Timestamp: 2016-02-14 04:21:33
Document Index: 265817726

Matched Legal Cases: ['§ 379', '§ 379', '§ 379', 'art 7', 'art 7', 'art 8', 'art 2']

21 U.S. Code § 379d–4 - Reporting requirements | US Law | LII / Legal Information Institute
U.S. Code › Title 21 › Chapter 9 › Subchapter VII › Part A › § 379d–4 21 U.S. Code § 379d–4 - Reporting requirements
Generic drugs Beginning with fiscal year 2013 and ending after fiscal year 2017, not later than 120 days after the end of each fiscal year for which fees are collected under subpart 7 of part C, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning, for all applications for approval of a generic drug under section 355
the number of such applications that met the goals identified for purposes of subpart 7 of part C, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record;
In general Beginning with fiscal year 2014, not later than 120 days after the end of each fiscal year for which fees are collected under subpart 8 of part C, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning—
So in original. Probably means subpart 2 of part C.